NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Goldman Sachs Upgrades Chime to Buy with Strong Upside Potential

Goldman Sachs upgrades Chime to Buy with a $27 price target, citing strong take-rate potential from the new Chime Card and revenue diversification strategy.

Goldman Sachs Upgrades Chime to Buy with Strong Upside Potential
Credit: Chime/Nasdaq
Already have an account? Sign in.
12/01/2025 · 10:04 AM
CHYM
/ Don’t stop at just one post.

Related↓

Chime to Buy Stride Bank for $590 Million and Bring Banking In-House
09/08/2026 · 5:40 PM

Chime to Buy Stride Bank for $590 Million and Bring Banking In-House

Stride becomes Chime Bank, N.A. $100M+ synergies expected. Immediately accretive. Closes H1 2027.

/ Subscriber only
/ Read more

Feed↓

Tyra’s SURF302 Data Missed the Street’s 70% CR Bar
09/09/2026 · 7:34 AM

Tyra’s SURF302 Data Missed the Street’s 70% CR Bar

60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.

/ Subscriber only
Sagimet Gets Wall Street Upgrade After China Acne Data and U.S. Trial Clearance
09/09/2026 · 7:02 AM

Sagimet Gets Wall Street Upgrade After China Acne Data and U.S. Trial Clearance

Barclays says Sagimet’s dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027.

/ Subscriber only
Novartis Failure Raises Questions for Dyne’s 2027 DM1 Readout
Featured/ 09/09/2026 · 6:19 AM

Novartis Failure Raises Questions for Dyne’s 2027 DM1 Readout

Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe